Cingulate Inc CING

$5.26 +0.15 (2.94%)

Valuation

Market cap
70,625,000
Revenue TTM
$0
Net income TTM
$-22,450,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
607,200
Avg volume
166,356
Day's range
$5.03 – $5.40
Shares out
14,963,000
Stochastic %K
80%
Beta
-0.88
Analysts
Strong Buy
Price target
$21.20

Price

Company profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-210...

Show more

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Industry
Biotechnology
Sector
Healthcare
Phone
913 942 2300
Website
https://www.cingulate.com
Address
1901 West 47th Place, Kansas City, United States

Latest news

Stocktwits

afgncap Nov 19, 10:40 PM 0 replies
prismmarketview Nov 19, 7:13 PM
$CING: U.S. Patent No. 12,797,335 (trimodal, precision-timed release buspirone tablet) for CTx-2103 (anxiety, investigational) → Formulation patent, not a patent on buspirone → Priority is still resubmitting the CTx-1301 (ADHD) application; 2H 2027 target if approved Caveats: IP only. CTx-2103 development starts after CTx-1301 approval, with no timeline. $CING #Biotech https://prismmarketview.com/cingulate-secures-u-s-patent-for-anxiety-drug-formulation-keeps-focus-on-adhd-candidate/
0 replies
Spicy_Weeklies Nov 19, 4:52 PM
$CING “the holy grail for ADHD” https://www.psychiatrictimes.com/shorts/potential-of-ctx-1301-for-adhd $SLS $INO $PYPD
0 replies
The_Baba_Yaga Nov 19, 4:25 PM
$CING Why are the shorts so weak here?
0 replies
STACKD0E Nov 19, 4:13 PM 0 replies
FUD_Slayer Nov 19, 3:59 PM
$CING Anything below $5 and I’m adding aggressively
0 replies
DARKP00L Nov 19, 2:59 PM
$CING 09:29 on Nov. 19 2026 Cingulate Announces U.S. Patent Issuance for CTx-2103, Further Validating PTR™ Technology Platform
0 replies
Jojo_Mojo12 Nov 19, 2:43 PM
$CING ADHD and anxiety patent is huge. I’d think they would adjust Price target?
0 replies